Tonix Pharmaceuticals Holding Corp (TNXP) - News Archive

Tonix Pharmaceuticals Making Strides in PTSD, Asian Market, and Fibromyalgia TreatmentTonix Pharmaceuticals, a leading biopharmaceutical company focused on researching and developing innovative medications for challengi...

Tonix Pharmaceuticals, a biopharmaceutical company focusing on the development and commercialization of innovative therapies, recently announced its collaboration with EVERSANA for the launch strategy and commercializat...

Tonix Pharmaceuticals Progresses in the Development of TNX-1500 and Its Potential Impact on Kidney Transplant RejectionWith the increasing demand for organ transplantation worldwide, finding effective ways to prevent gr...

Tonix Pharmaceuticals recently announced positive results from a clinical pharmacokinetic bridging study of Tonmya, a potential treatment for posttraumatic stress disorder (PTSD). The study aimed to support the developm...

Tonix Pharmaceuticals, a leading biopharmaceutical company, recently hosted a KOL webinar discussing the positive results from the Phase 3 clinical trial of their drug Tonmya for the treatment of fibromyalgia. The compa...

The recent announcement by Tonix Pharmaceuticals regarding the FDA Investigational New Drug (IND) clearance for their trial of TNX-102 SL has sparked considerable interest in the medical community. This groundbreaking d...

In a significant revelation underlining the intersection of fibromyalgia and long COVID, Tonix Pharmaceuticals has recently announced its research findings. The reported study indicates that pre-existing fibromyalgia-ty...

Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Trade Name for TNX-102 SL for the Management of FibromyalgiaTonix Pharmaceuticals recently revealed that its potential breakthrough drug, TNX-102 SL, m...

Tonix Pharmaceuticals recently presented additional data from its second positive Phase 3 clinical trial, highlighting the favorable tolerability and differentiated side effect profile of TNX-102 SL for the management o...

In a groundbreaking move for Tonix Pharmaceuticals Holding, the company recently announced a Registered Direct Offering of up to $144 million. This development has garnered considerable attention from healthcare-focused...

Tonix Pharmaceuticals Holding Corp. has announced the significant success of its second Phase 3 clinical trial for TNX-102 SL, its lead drug candidate for the management of fibromyalgia. The results from the Phase 3 RES...